Skip to Main Content
Phase III

Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI

  • Study HIC#:2000022741
  • Last Updated:11/21/2018

This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution.

Approximately 700 subjects who have been diagnosed with CRBSI/CLABSI and who meet all necessary criteria for the study will be randomized in a 1:1 ratio to 1 of 2 treatment arms:

  • MLT Arm: MLT + SOC intravenous (IV) antibiotic therapy; or
  • Control Arm: Antibiotic lock (┬▒heparin) + SOC IV antibiotics. The antibiotic lock (ALT) should be comprised of the best available therapy at the sites based on standard institutional practices or recommendations from the Infectious Diseases Society of America (IDSA) guidelines.
  • Age12 years and older
  • GenderBoth
  • Start Date08/21/2018
  • End Date06/29/2018

Trial Purpose and Description

This is a Phase 3, multi-center, randomized, double-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that combines minocycline with edetate disodium in 25% ethanol solution.

Eligibility Criteria

Inclusion Criteria:

  1. Male or female at least 12 years of age;
  2. Subject must have a bloodstream infection with no other apparent source that is not related to an infection at another site that meets one of the following:
    1. A recognized single pathogen cultured from 1 or more blood cultures; OR
    2. A common skin contaminant cultured from 2 or more blood cultures drawn on the same or consecutive calendar days from a subject with fever (greater than 38.0 degrees C), chills, or hypotension (systolic blood pressure less than 90 mmHg);
  3. Inpatient or outpatient with presence of indwelling CVC (ie, totally implantable port, tunneled or non-tunneled CVC, hemodialysis catheter, or peripherally inserted CVC) that has been in place for greater than5 days from which a bloodstream infection has been documented within 96 hours prior to enrollment (and from which an isolate of the baseline pathogen(s) is still available for analysis at the central laboratory) and demonstrates the protocol definition of CRBSI/CLABSI; NOTE: For the treatment arm only (MLT Arm and Control Arm), the CVC is expected to be in place through the end of treatment.
  4. Subjects who refuse to have their catheter removed or subjects for whom, in the Investigator's opinion, catheter retention for the duration of the study is reasonable or required;
  5. Female subjects of childbearing potential must have a negative urine and/or serum pregnancy test within 5 days prior to randomization (MLT Arm and Control Arm) ;
  6. Male subjects must agree to refrain from sperm donation throughout the duration of the study and for 90 days following the last dose of study drug;
  7. Subjects eligible for the Observation Arm must have had their central line removed and replaced within 96 hours of the qualifying blood culture (120 hours with Medical Monitor approval);

Exclusion Criteria:

  1. Subjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium;
  2. Subjects with septic shock that requires inotropic support or is unresponsive to fluid resuscitation;
  3. Subjects taking disulfiram or disulfiram-like drugs;
  4. Subjects with prosthetic cardiac valves, vascular grafts, pacers, or other non-removable vascular foreign body, with the exception of coronary stents and peripheral stents;
  5. Subjects with the presence of a deep-seated intravascular source of infection (eg, endocarditis [as evidenced by vegetations on an echocardiogram or clinical suspicion] or septic thrombosis);
  6. Subjects with bacteremia with documented microbiological evidence of another source of infection (eg, osteomyelitis, pneumonia, skin infection, urinary tract infection, joint infection, or abdominal infection) known to be due to the same organism cultured from the blood;
  7. Subjects with polymicrobial CRBSI/CLABSI caused by pathogens that would require multiple antibiotics to be used for adequate lock therapy treatment. For example, a subject with methicillin-resistant Staphylococcus aureus and Escherichia coli requiring treatment with vancomycin and meropenem would be excluded from the study. A subject with S. aureus and Staphylococcus epidermidis, where both are identified as pathogens and where both could be treated with vancomycin, would be eligible;
  8. Subjects with the presence of a tunnel or catheter exit site infection or an infusion port pocket abscess as manifested by purulence at the exit site, or inflammation with erythema, or induration of greater than 1 cm in diameter;
  9. Subjects who have been previously randomized into the present study;
  10. Subjects who are pregnant or lactating;
  11. Subjects with proven or suspected persistent bacteremia despite 72 hours of both systemic antibiotic therapy and lock therapy to which the infecting organism is susceptible;
  12. Subjects with short-term CVCs indwelling less than 5 days;
  13. Subjects with a central line-related mycobacterial infection; or
  14. Subjects who, in the opinion of the Investigator, have a high probability of death within 3 months of randomization due to a disease process other than the CRBSI/CLABSI

Sub-Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: